CureVac Deferred Long Term Liab vs Non Current Liabilities Total Analysis
CVAC Stock | USD 2.93 0.05 1.74% |
CureVac NV financial indicator trend analysis is way more than just evaluating CureVac NV prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CureVac NV is a good investment. Please check the relationship between CureVac NV Deferred Long Term Liab and its Non Current Liabilities Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
Deferred Long Term Liab vs Non Current Liabilities Total
Deferred Long Term Liab vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CureVac NV Deferred Long Term Liab account and Non Current Liabilities Total. At this time, the significance of the direction appears to have very week relationship.
The correlation between CureVac NV's Deferred Long Term Liab and Non Current Liabilities Total is 0.27. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of CureVac NV, assuming nothing else is changed. The correlation between historical values of CureVac NV's Deferred Long Term Liab and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of CureVac NV are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Deferred Long Term Liab i.e., CureVac NV's Deferred Long Term Liab and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | 0.27 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Non Current Liabilities Total
Most indicators from CureVac NV's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CureVac NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.At present, CureVac NV's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 25.8M | 26.4M | 26.7M | 19.2M | Interest Income | 10.1M | 4.0M | 12.9M | 13.6M |
CureVac NV fundamental ratios Correlations
Click cells to compare fundamentals
CureVac NV Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CureVac NV fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 130.6M | 1.5B | 1.2B | 860.5M | 788.9M | 838.8M | |
Other Current Liab | 13.3M | 68.8M | 176.3M | 46.2M | 90.5M | 74.8M | |
Total Current Liabilities | 28.1M | 247.6M | 357.7M | 156.2M | 186.5M | 184.1M | |
Total Stockholder Equity | (42.8M) | 711.3M | 688.5M | 533.3M | 517.4M | 447.3M | |
Net Tangible Assets | (48.2M) | 697.9M | 676.2M | 501.5M | 576.7M | 407.8M | |
Property Plant And Equipment Net | 66.8M | 104.8M | 200.4M | 241.7M | 278.9M | 172.0M | |
Current Deferred Revenue | 7.5M | 158.0M | 55.8M | 36.8M | 44.6M | 56.5M | |
Net Debt | 48.5M | (1.3B) | (782.6M) | (453.7M) | (360.9M) | (379.0M) | |
Retained Earnings | (515.9M) | (645.1M) | (1.1B) | (1.3B) | (1.6B) | (1.5B) | |
Accounts Payable | 5.3M | 17.6M | 122.3M | 68.2M | 46.4M | 49.3M | |
Cash | 30.7M | 1.3B | 811.5M | 495.8M | 402.8M | 565.5M | |
Non Current Assets Total | 73.4M | 121.5M | 218.2M | 276.4M | 310.1M | 192.9M | |
Non Currrent Assets Other | 967K | 1.1M | 1.2M | 1.7M | (14.2M) | (13.5M) | |
Other Assets | 6.3M | 7.5M | 5.6M | 3.0M | 1.0 | 0.95 | |
Cash And Short Term Investments | 32.1M | 1.3B | 816.1M | 500.3M | 402.8M | 575.1M | |
Net Receivables | 17.7M | 1.8M | 18.5M | 39.4M | 35.9M | 22.0M | |
Common Stock Shares Outstanding | 186.9M | 132.2M | 186.0M | 189.1M | 220.8M | 200.0M | |
Short Term Investments | 1.5M | 2.6M | 4.6M | 4.5M | 2.7M | 2.5M | |
Liabilities And Stockholders Equity | 130.6M | 1.5B | 1.2B | 860.5M | 788.9M | 838.8M | |
Non Current Liabilities Total | 145.3M | 552.4M | 112.0M | 171.0M | 85.0M | 150.8M | |
Capital Lease Obligations | 14.1M | 55.3M | 28.9M | 42.1M | 41.8M | 33.4M | |
Inventory | 6.2M | 14.5M | 56.2M | 24.0M | 24.8M | 23.6M | |
Other Current Assets | 1.2M | 48.3M | 49.2M | 5.3M | 15.2M | 22.3M | |
Other Stockholder Equity | 493.4M | 1.4B | (5.8M) | (1.5M) | 2.1B | 2.2B | |
Total Liab | 173.4M | 800.0M | 469.8M | 327.2M | 271.5M | 391.5M | |
Deferred Long Term Liab | 966K | 1.0M | 515K | 302K | 271.8K | 258.2K | |
Net Invested Capital | 22.2M | 711.3M | 688.5M | 533.3M | 516.9M | 459.1M | |
Property Plant And Equipment Gross | 61.7M | 104.8M | 247.4M | 258.7M | 301.8M | 186.0M | |
Total Current Assets | 57.2M | 1.4B | 940.0M | 584.0M | 478.8M | 645.9M | |
Accumulated Other Comprehensive Income | 472.4M | 1.3B | 1.7B | 1.8B | (67.1K) | (63.7K) | |
Non Current Liabilities Other | 529K | 284K | 264K | 19K | 17.1K | 16.2K | |
Net Working Capital | 29.1M | 1.1B | 582.3M | 427.8M | 292.0M | 461.7M | |
Short Term Debt | 2.0M | 3.2M | 3.5M | 5.0M | 5.0M | 3.5M | |
Intangible Assets | 5.7M | 14.1M | 13.2M | 19.3M | 15.9M | 13.7M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CureVac NV in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CureVac NV's short interest history, or implied volatility extrapolated from CureVac NV options trading.
Pair Trading with CureVac NV
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CureVac NV position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CureVac NV will appreciate offsetting losses from the drop in the long position's value.Moving against CureVac Stock
0.72 | VRCA | Verrica Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
0.58 | VIRI | Virios Therapeutics Llc | PairCorr |
0.58 | HOOK | Hookipa Pharma | PairCorr |
0.47 | ELYM | Eliem Therapeutics | PairCorr |
0.44 | ELDN | Eledon Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to CureVac NV could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CureVac NV when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CureVac NV - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CureVac NV to buy it.
The correlation of CureVac NV is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CureVac NV moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CureVac NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CureVac NV can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.Note that the CureVac NV information on this page should be used as a complementary analysis to other CureVac NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is CureVac NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.243 | Quarterly Revenue Growth 0.931 | Return On Assets (0.21) | Return On Equity (0.50) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.